Skip to content
etf.net

BIB vs QLD

ProShares Ultra Nasdaq Biotechnology

BIBBNasdaq

ProShares Ultra QQQ

QLDANYSE Arca

Overlap

26.2%by weight

Expense ratio

QLD −0.06pt a year

BIB0.95%QLD0.89%

Avg volume · 30D

QLD 395.7×the volume

BIB10.5KQLD4.15M

10Y return · a year

QLD +19.3pt

BIB+12.6%QLD+31.9%

BIB vs QLD Performance

Oct 29, 2021 – Oct 30, 2026

+36.3%BIB+97.9%QLD

Oct 29, 2021 to Oct 30, 2026. BIB +36.3%. QLD +97.9%. Use the arrow keys to read each point.−50%0%150%Oct 2021Apr 2024Oct 2026
Expense ratio
BIB 0.95%
QLD 0.89%, better
Fund size
BIB $104M
QLD $13.3B
1Y total return
BIB +68.9%, better
QLD +10.7%
Yield (12M)
BIB 0.19%, better
QLD 0.15%
Holdings
BIB 247
QLD 113
Avg volume (30D)
BIB 10.5K sh
QLD 4.15M sh, better
NAV per share
BIB $120.62
QLD $82.56
52W range

ETF.net Grade

BIB: Cost 51, Risk 70, Mission not scored, Tradability 84, Holdings 60, Durability 75. QLD: Cost 72, Risk 66, Mission 95, Tradability 100, Holdings 72, Durability 81.
Pillar letters and Scores for BIB, QLD, with each pillar’s weight
PillarBIBQLD
Cost30% weightC51A72Higher
Mission25% weightNot scoredA95
Risk15% weightA70HigherB66
Tradability15% weightA84A100Higher
Holdings10% weightB60A72Higher
Durability5% weightA75A81Higher

Rank among Leveraged Long (2x & Other) funds

How we build Categories ›
Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

Same Category. BIB and QLD are both graded against the same 95 Leveraged Long (2x & Other) funds, so their Grades compare head to head.

Leveraged Long (2x & Other)⁠

Category · 95 funds
See all 95 ›

QLD ranks 1st and BIB 8th of 95 funds in the Leveraged Long (2x & Other) Category.

  1. Rank 1AQLDProShares Ultra QQQScore 77
  2. Rank 2AUYGProShares Ultra FinancialsScore 74
  3. Rank 7BUJBProShares Ultra High YieldScore 65
  4. Rank 8BBIBProShares Ultra Nasdaq BiotechnologyScore 64
  5. Rank 9BMVVProShares Ultra MidCap400Score 63

Our read on each fund

ETF.net Research

BIBBProShares Ultra Nasdaq Biotechnology

QLDAProShares Ultra QQQ

In short

BIB Biotech with the dial at 2x, not 3x. Since 2010 BIB has aimed at twice the daily move of the Nasdaq Biotechnology Index, a modified cap-weighted set of Nasdaq-listed biotech and pharma names, reset fresh every single day.

QLD The 2x dial on the Nasdaq-100. QLD aims for twice the index's daily move, half the dose of the 3x crowd, and it has been running that playbook since 2006. The multiple resets every session.

Stated mandate

BIB The Fund seeks daily investment results, before fees and expenses, that correspond to two times the daily performance of the Nasdaq Biotechnology Index.

QLD The fund seeks daily investment results, before fees and expenses, equal to twice the daily performance of the Nasdaq-100 Index.

Why people hold it

  • BIB Aims for two times the daily move of the Nasdaq Biotechnology Index. Magnified biotech exposure through one ticker in a regular brokerage account, no margin agreement needed.proshares.com
  • The benchmark dates to 1993: Nasdaq-listed biotech and pharma, modified cap-weighted, roughly 300 stocks. Industry-wide exposure, not a handful of lottery tickets.nasdaqomx.comnasdaqomx.com 2
  • 0.95% net of a waiver through September 30, 2027, against a 1.17% gross. Near the category median and level with ProShares stablemate DDM at 0.95%.
  • Live since 2010 through several biotech boom-and-bust cycles, and it stands among the stronger implementations in a crowded leveraged-bull field.
  • QLD Costs 0.89% net of a waiver through September 30, 2027 (0.96% gross), below the leveraged-bull category median and under Ultra stablemates ROM (0.93%) and DDM (0.95%).
  • Hits its stated daily 2x mark with very little drift, one of the tighter implementations among the roughly 100 leveraged bull funds in its group.
  • A multi-billion-dollar, actively traded fund, so entering and exiting rarely means hunting for the other side of the trade.
  • Trading since June 2006, which makes it one of the longest-running leveraged equity funds on the US shelf rather than a recent product-shelf experiment.

Worth knowing

  • BIB Daily reset. Hold past one day and compounding takes over: returns can differ in amount, and even direction, from 2x the index over that stretch.proshares.com
  • One industry, doubled. Trial readouts and FDA decisions move biotech hard, and this fund is built to amplify those days in both directions.proshares.com
  • Among the lighter-traded, smaller funds in its category, so spreads and order size matter more here than with the headline leveraged names.
  • QLD The 2x objective covers one day only. Hold longer and daily resets plus compounding can push results away from twice the index's move over that stretch, in either direction.proshares.com
  • Magnification runs both ways: a down day in the Nasdaq-100 lands on shareholders at roughly double size, same as an up day.
  • Cheap for geared exposure, still well above a plain unleveraged Nasdaq-100 tracker. The waiver is set to lapse September 30, 2027, after which the 0.96% gross rate applies unless renewed.

Full BIB profile⁠

Full QLD profile⁠

BIB vs QLD Holdings

How BIB and QLD differ

Overlap by weight

26.2%

Shared holdings make up 62.9% of BIB and 26.2% of QLD.

Level by level

  • Sector10 Sectors16.3%
  • Holdings7 in both26.2%
  • Countryby domicile96.4%
  • Asset classEquity100%

Sector

Sector weights in BIB and QLD, widest gap first
SectorMore in BIBMore in QLD
Health CareBIB +73.9 points
TechnologyQLD +52.3 points
FinancialsBIB +9.8 points
CommunicationQLD +9.6 points
Consumer DiscretionaryQLD +9.2 points
Consumer StaplesQLD +5.5 points
IndustrialsQLD +4.9 points
UtilitiesQLD +1.0 points
MaterialsQLD +0.9 points
EnergyQLD +0.4 points

Country, concentration and asset class

Country by domicile

Country weights in BIB and QLD, widest gap first
CountryMore in BIBMore in QLD
United StatesQLD +2.1 points
United KingdomBIB +1.8 points
FranceBIB +0.9 points
CanadaQLD +0.6 points
Other countries (10)Same weight

Concentration

Weight in the 10 largest Holdings

  • BIB66.4%
  • QLD53.3%

Securities held

  • BIB246
  • QLD112

Asset class

BIB
Equity
QLD
Equity

Holdings

  • Only in BIB239
  • In both7
  • Only in QLD105

Only in BIB

239 securities, 37.1% of BIB by weight

  • Revolution Medicines Inc1.58%
  • Biogen Inc1.44%
  • Illumina Inc1.37%

Only in QLD

105 securities, 73.8% of QLD by weight

  • Apple Inc5.88%
  • NVIDIA Corp5.76%
  • Microsoft Corp4.53%

Weight gaps

All 7 Holdings in both funds, largest gap first.

Holding weights in BIB and QLD, widest gap first
HoldingMore in BIBMore in QLD
Proshares Genius Mny Mkt EtfIQMMBIB +5.54 points
Gilead Sciences IncGILDBIB +4.81 points
Vertex Pharmaceuticals IncVRTXBIB +4.37 points
Amgen IncAMGNBIB +4.29 points
Regeneron PharmaceuticalsREGNBIB +3.31 points
Moderna IncMRNABIB +3.12 points
Alnylam Pharmaceuticals IncALNYBIB +0.78 points

All 274 BIB holdings⁠All 121 QLD holdings⁠

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

BIB vs QLD Cost

Overpaying BIB vs QLD

$997

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • BIB 0.95%

    $17,869

  • QLD 0.89%

    $16,872

$10,000
30 years

Cost over time

  • BIB 0.95%
  • QLD 0.89%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$5K$10K$15K$20K051015202530BIB $17,869QLD $16,872

Year by year

YearBIBQLDOverpaying
10$1,678$1,576$102
20$6,322$5,953$369
30$17,869$16,872$997

Expense ratio

  • 0.95%BIB
  • 0.89%QLD, cheaper
  • Middle half of Leveraged Long (2x & Other) funds
  • Median 0.95%

QLD 28th cheapest of 95 funds

BIB 32nd cheapest of 95 funds

BIB vs QLD Dividends

Last 12 months to Oct 30, 2026
Yield (12M)
BIB 0.19%, better
QLD 0.15%
Payout (12M)
BIB $0.22
QLD $0.12
Last payment
BIB $0.08
QLD $0.03
Ex-dividend
BIB Sep 23, 2026
QLD Sep 23, 2026
Paid on
BIB Sep 29, 2026
QLD Sep 29, 2026
Frequency
BIB Twice a year
QLD Quarterly

Distribution history

Per share, 2017 to 2026, same scale for both

BIBTwice a year · 12 paymentsAll BIB payments⁠
One bar per payment. 12 payments from 2017 to 2026 YTD. Dec 22, 2022 $0.02; Dec 20, 2023 $0.04; Mar 20, 2024 $0.04; Jun 26, 2024 $0.26; Sep 25, 2024 $0.15; Dec 23, 2024 $0.40; Mar 26, 2025 $0.13; Jun 25, 2025 $0.17; Sep 24, 2025 $0.18; Dec 24, 2025 $0.13; Mar 25, 2026 $0.0071; Sep 23, 2026 $0.08. Use the arrow keys to read each point.$0$0.252017202020232026YTD
QLDQuarterly · 21 paymentsAll QLD payments⁠
One bar per payment. 21 payments from 2017 to 2026 YTD. Mar 22, 2017 $0.0012; Jun 21, 2017 $0.00044; Dec 26, 2018 $0.005; Mar 20, 2019 $0.0078; Jun 25, 2019 $0.0052; Dec 24, 2019 $0.0062; Mar 25, 2020 $0.0011; Dec 22, 2022 $0.05; Sep 20, 2023 $0.09; Dec 20, 2023 $0.04; Mar 20, 2024 $0.03; Jun 26, 2024 $0.05; Sep 25, 2024 $0.03; Dec 23, 2024 $0.03; Mar 26, 2025 $0.01; Jun 25, 2025 $0.06; Sep 24, 2025 $0.02; Dec 24, 2025 $0.02; Mar 25, 2026 $0.01; Jun 24, 2026 $0.06; Sep 23, 2026 $0.03. Use the arrow keys to read each point.$0$0.252017202020232026YTD

BIB vs QLD Risk

Fall from peak · 5 years

  • BIB
  • QLD
Oct 29, 2021 to Oct 30, 2026. Worst fall: QLD −63.7% · Dec 2022. Use the arrow keys to read each point.−60%−40%−20%0%Oct 2021Apr 2024Oct 2026

Risk facts

VolatilityStd dev, 3 years
BIB 33.9%, betterQLD 36.7%
Return per unit of riskSharpe ratio, 3 years
BIB 1.12, betterQLD 1.04
Worst fallMax drawdown, 5 years
BIB −61.8%, betterQLD −63.7%
Market sensitivityBeta, 5 years
BIB 1.20QLD 2.46

BIB and QLD in the news

All news⁠

Popular comparisons

  • BIBBvsUYGA

    ProShares Ultra Nasdaq Biotechnology · ProShares Ultra Financials

    Expense ratio
    0.95% · 0.93%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • QLDAvsUYGA

    ProShares Ultra QQQ · ProShares Ultra Financials

    Expense ratio
    0.89% · 0.93%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BIBBvsROMA

    ProShares Ultra Nasdaq Biotechnology · ProShares Ultra Technology

    Expense ratio
    0.95% · 0.93%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • QLDAvsROMA

    ProShares Ultra QQQ · ProShares Ultra Technology

    Expense ratio
    0.89% · 0.93%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BIBBvsDDMB

    ProShares Ultra Nasdaq Biotechnology · ProShares Ultra Dow30

    Expense ratio
    0.95% · 0.95%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • QLDAvsDDMB

    ProShares Ultra QQQ · ProShares Ultra Dow30

    Expense ratio
    0.89% · 0.95%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.